Skip to main content
Top
Published in: Acta Neuropathologica Communications 1/2014

Open Access 01-12-2014 | Research

Posterior fossa and spinal gangliogliomas form two distinct clinicopathologic and molecular subgroups

Authors: Kirti Gupta, Wilda Orisme, Julie H Harreld, Ibrahim Qaddoumi, James D Dalton, Chandanamali Punchihewa, Racquel Collins-Underwood, Thomas Robertson, Ruth G Tatevossian, David W Ellison

Published in: Acta Neuropathologica Communications | Issue 1/2014

Login to get access

Abstract

Background

Gangliogliomas are low-grade glioneuronal tumors of the central nervous system and the commonest cause of chronic intractable epilepsy. Most gangliogliomas (>70%) arise in the temporal lobe, and infratentorial tumors account for less than 10%. Posterior fossa gangliogliomas can have the features of a classic supratentorial tumor or a pilocytic astrocytoma with focal gangliocytic differentiation, and this observation led to the hypothesis tested in this study - gangliogliomas of the posterior fossa and spinal cord consist of two morphologic types that can be distinguished by specific genetic alterations.

Results

Histological review of 27 pediatric gangliogliomas from the posterior fossa and spinal cord indicated that they could be readily placed into two groups: classic gangliogliomas (group I; n = 16) and tumors that appeared largely as a pilocytic astrocytoma, but with foci of gangliocytic differentiation (group II; n = 11). Detailed radiological review, which was blind to morphologic assignment, identified a triad of features, hemorrhage, midline location, and the presence of cysts or necrosis, that distinguished the two morphological groups with a sensitivity of 91% and specificity of 100%. Molecular genetic analysis revealed BRAF duplication and a KIAA1549-BRAF fusion gene in 82% of group II tumors, but in none of the group I tumors, and a BRAF:p.V600E mutation in 43% of group I tumors, but in none of the group II tumors.

Conclusions

Our study provides support for a classification that would divide infratentorial gangliogliomas into two categories, (classic) gangliogliomas and pilocytic astrocytomas with gangliocytic differentiation, which have distinct morphological, radiological, and molecular characteristics.
Appendix
Available only for authorised users
Literature
1.
go back to reference Becker AJ, Wiestler OD, Figarella-Branger D: WHO classification of tumors of the central nervous system. In Ganglioglioma and Gangliocytoma. 4th edition. Edited by: Bosman FT. Lyon, France: International Agency for Research on Cancer (IARC); 2007. Becker AJ, Wiestler OD, Figarella-Branger D: WHO classification of tumors of the central nervous system. In Ganglioglioma and Gangliocytoma. 4th edition. Edited by: Bosman FT. Lyon, France: International Agency for Research on Cancer (IARC); 2007.
2.
go back to reference Blumcke I, Wiestler OD: Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002, 61(7):575–584.CrossRefPubMed Blumcke I, Wiestler OD: Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002, 61(7):575–584.CrossRefPubMed
3.
go back to reference Kalyan-Raman UP, Olivero WC: Ganglioglioma: a correlative clinicopathological and radiological study of ten surgically treated cases with follow-up. Neurosurgery 1987, 20(3):428–433. 10.1227/00006123-198703000-00012CrossRefPubMed Kalyan-Raman UP, Olivero WC: Ganglioglioma: a correlative clinicopathological and radiological study of ten surgically treated cases with follow-up. Neurosurgery 1987, 20(3):428–433. 10.1227/00006123-198703000-00012CrossRefPubMed
4.
go back to reference Luyken C, et al.: Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 2004, 101(1):146–155. 10.1002/cncr.20332CrossRefPubMed Luyken C, et al.: Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 2004, 101(1):146–155. 10.1002/cncr.20332CrossRefPubMed
5.
go back to reference Baussard B, et al.: Pediatric infratentorial gangliogliomas: a retrospective series. J Neurosurg 2007, 107(4 Suppl):286–291.CrossRefPubMed Baussard B, et al.: Pediatric infratentorial gangliogliomas: a retrospective series. J Neurosurg 2007, 107(4 Suppl):286–291.CrossRefPubMed
6.
go back to reference Jallo GI, Freed D, Epstein FJ: Spinal cord gangliogliomas: a review of 56 patients. J Neurooncol 2004, 68(1):71–77.CrossRefPubMed Jallo GI, Freed D, Epstein FJ: Spinal cord gangliogliomas: a review of 56 patients. J Neurooncol 2004, 68(1):71–77.CrossRefPubMed
7.
go back to reference Lagares A, et al.: Ganglioglioma of the brainstem: report of three cases and review of the literature. Surg Neurol 2001, 56(5):315–322. discussion 322–4 10.1016/S0090-3019(01)00618-8CrossRefPubMed Lagares A, et al.: Ganglioglioma of the brainstem: report of three cases and review of the literature. Surg Neurol 2001, 56(5):315–322. discussion 322–4 10.1016/S0090-3019(01)00618-8CrossRefPubMed
9.
go back to reference Westwood DA, MacFarlane MR: Pontomedullary ganglioglioma: a rare tumour in an unusual location. J Clin Neurosci 2009, 16(1):108–110. 10.1016/j.jocn.2007.11.016CrossRefPubMed Westwood DA, MacFarlane MR: Pontomedullary ganglioglioma: a rare tumour in an unusual location. J Clin Neurosci 2009, 16(1):108–110. 10.1016/j.jocn.2007.11.016CrossRefPubMed
10.
go back to reference Lang FF, et al.: Central nervous system gangliogliomas. Part 2: clinical outcome. J Neurosurg 1993, 79(6):867–873. 10.3171/jns.1993.79.6.0867CrossRefPubMed Lang FF, et al.: Central nervous system gangliogliomas. Part 2: clinical outcome. J Neurosurg 1993, 79(6):867–873. 10.3171/jns.1993.79.6.0867CrossRefPubMed
11.
go back to reference Dougherty MJ, et al.: Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010, 12(7):621–630. 10.1093/neuonc/noq007CrossRefPubMedPubMedCentral Dougherty MJ, et al.: Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010, 12(7):621–630. 10.1093/neuonc/noq007CrossRefPubMedPubMedCentral
12.
go back to reference Forshew T, et al.: Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009, 218(2):172–181. 10.1002/path.2558CrossRefPubMed Forshew T, et al.: Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009, 218(2):172–181. 10.1002/path.2558CrossRefPubMed
13.
go back to reference Pfister S, et al.: BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008, 118(5):1739–1749. 10.1172/JCI33656CrossRefPubMedPubMedCentral Pfister S, et al.: BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008, 118(5):1739–1749. 10.1172/JCI33656CrossRefPubMedPubMedCentral
14.
go back to reference Schindler G, et al.: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121(3):397–405. 10.1007/s00401-011-0802-6CrossRefPubMed Schindler G, et al.: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121(3):397–405. 10.1007/s00401-011-0802-6CrossRefPubMed
15.
go back to reference Jeuken JW, Wesseling P: MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol 2010, 222(4):324–328. 10.1002/path.2780CrossRefPubMed Jeuken JW, Wesseling P: MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol 2010, 222(4):324–328. 10.1002/path.2780CrossRefPubMed
16.
go back to reference Jones DT, et al.: MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 2012, 69(11):1799–1811. 10.1007/s00018-011-0898-9CrossRefPubMed Jones DT, et al.: MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 2012, 69(11):1799–1811. 10.1007/s00018-011-0898-9CrossRefPubMed
17.
18.
go back to reference Tatevossian RG, et al.: MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010, 222(3):509–514.PubMed Tatevossian RG, et al.: MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010, 222(3):509–514.PubMed
19.
go back to reference Zhang J, et al.: Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013, 45(6):602–612. 10.1038/ng.2611CrossRefPubMedPubMedCentral Zhang J, et al.: Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013, 45(6):602–612. 10.1038/ng.2611CrossRefPubMedPubMedCentral
20.
go back to reference Zhang S, et al.: Brainstem gangliogliomas: a retrospective series. J Neurosurg 2013, 118(4):884–888. 10.3171/2013.1.JNS121323CrossRefPubMed Zhang S, et al.: Brainstem gangliogliomas: a retrospective series. J Neurosurg 2013, 118(4):884–888. 10.3171/2013.1.JNS121323CrossRefPubMed
21.
go back to reference Cin H, et al.: Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011, 121(6):763–774. 10.1007/s00401-011-0817-zCrossRefPubMed Cin H, et al.: Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011, 121(6):763–774. 10.1007/s00401-011-0817-zCrossRefPubMed
22.
go back to reference Dahiya S, et al.: BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013, 125(6):901–910. 10.1007/s00401-013-1120-yCrossRefPubMed Dahiya S, et al.: BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013, 125(6):901–910. 10.1007/s00401-013-1120-yCrossRefPubMed
23.
go back to reference Dias-Santagata D, et al.: BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011, 6(3):e17948. 10.1371/journal.pone.0017948CrossRefPubMedPubMedCentral Dias-Santagata D, et al.: BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011, 6(3):e17948. 10.1371/journal.pone.0017948CrossRefPubMedPubMedCentral
24.
go back to reference Janzarik WG, et al.: Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007, 38(2):61–63. 10.1055/s-2007-984451CrossRefPubMed Janzarik WG, et al.: Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007, 38(2):61–63. 10.1055/s-2007-984451CrossRefPubMed
25.
go back to reference Komori T, Scheithauer BW, Hirose T: A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol 2002, 26(5):582–591. 10.1097/00000478-200205000-00004CrossRefPubMed Komori T, Scheithauer BW, Hirose T: A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol 2002, 26(5):582–591. 10.1097/00000478-200205000-00004CrossRefPubMed
26.
go back to reference Preusser M, et al.: Rosette-forming glioneuronal tumor of the fourth ventricle. Acta Neuropathol 2003, 106(5):506–508. 10.1007/s00401-003-0758-2CrossRefPubMed Preusser M, et al.: Rosette-forming glioneuronal tumor of the fourth ventricle. Acta Neuropathol 2003, 106(5):506–508. 10.1007/s00401-003-0758-2CrossRefPubMed
27.
go back to reference Gessi M, et al.: Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT). J Neurooncol 2012, 110(1):21–25. 10.1007/s11060-012-0940-2CrossRefPubMed Gessi M, et al.: Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT). J Neurooncol 2012, 110(1):21–25. 10.1007/s11060-012-0940-2CrossRefPubMed
Metadata
Title
Posterior fossa and spinal gangliogliomas form two distinct clinicopathologic and molecular subgroups
Authors
Kirti Gupta
Wilda Orisme
Julie H Harreld
Ibrahim Qaddoumi
James D Dalton
Chandanamali Punchihewa
Racquel Collins-Underwood
Thomas Robertson
Ruth G Tatevossian
David W Ellison
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Acta Neuropathologica Communications / Issue 1/2014
Electronic ISSN: 2051-5960
DOI
https://doi.org/10.1186/2051-5960-2-18

Other articles of this Issue 1/2014

Acta Neuropathologica Communications 1/2014 Go to the issue